Peter Silvester serves as Senior Vice President and President of Life Sciences Solutions at Thermo Fisher Scientific.
Mr.Silvester provides executive oversight of Thermo Fisher’s biosciences, genetic sciences and clinical next-generation sequencing businesses as well as life sciences finance, legal, HR, licensing and commercial supply functions. He is a Board Member of Coriell Life Sciences and Executive Board Member of Biocom.
“Programs which engage all stakeholders academia, industry, clinicians and patients – to deliver real-world evidence and economic value models to policy makers, regulatory agencies and payers, are what is needed to catalyze the adoption of precision medicine”
According to the U.S. Food & Drug Administration, pharmacogenomics is an important part of precision medicine. FDA has an interest in determining how a person’s genetic makeup may affect their response to a drug, and how this can assist healthcare providers in “choosing a drug that is more likely to work, avoiding drugs that might have side effects, adjusting the dose of a drug, or determining if closer monitoring is needed.” says Peter Silvester